Amarin Corporation PLC (AMRN) : Zacks Investment Research ranks Amarin Corporation PLC (AMRN) as 2, which is a Buy recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 3 research analysts is 1, which indicates as a Strong Buy.
Amarin Corporation PLC (AMRN) : The highest short term price target forecast on Amarin Corporation PLC (AMRN) is $10 and the lowest target price is $5. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $6.83 with a standard deviation of $2.84.
Shares of Amarin Corporation plc rose by 2.58% in the last five trading days and 33.61% for the last 4 weeks. Amarin Corporation plc is up 73.77% in the last 3-month period. Year-to-Date the stock performance stands at 68.25%. Amarin Corporation PLC (NASDAQ:AMRN): stock turned positive on Tuesday. Though the stock opened at $3.18, the bulls momentum made the stock top out at $3.25 level for the day. The stock recorded a low of $3.16 and closed the trading day at $3.18, in the green by 0.95%. The total traded volume for the day was 2,398,972. The stock had closed at $3.15 in the previous days trading.
Amarin Corporation plc (Amarin) is a biopharmaceutical company. The Company is engaged in the commercialization and development of therapeutics for cardiovascular health. Amarins lead product, Vascepa (icosapent ethyl) capsules, are used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (triglyceride or TG over 500 milligrams per deciliter) hypertriglyceridemia. The Company sells Vascepa principally to various wholesalers, as well as regional wholesalers and specialty pharmacy providers, who in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. Vascepa is available in the United States by prescription only. Amarin is also developing Vascepa for the treatment of patients with high (TG over 200 milligrams per deciliter and less than 500 milligrams per deciliter) triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (LDL-C) levels.